双特异性磷酸酶12通过抑制脂肪生成和凋亡信号调节激酶1通路调节肝脏脂质代谢
研究探讨双特异性磷酸酶12(DUSP12)在非酒精性脂肪性肝病(NAFLD)中的作用。在L02细胞中,DUSP12可减轻棕榈酸/油酸处理后的肝脂肪变性和炎症;肝细胞特异性DUSP12缺失小鼠在高脂饮食和高脂高胆固醇饮食下出现高胰岛素血症、肝脂肪变性和胰岛素敏感性下降,而过表达DUSP12可减轻高脂饮食诱导的肝脂肪变性、胰岛素抵抗和炎症。机制上DUSP12与ASK1结合并促进其去磷酸化,抑制JNK和p38 MAPK通路。
要点
- DUSP12在L02细胞中减轻棕榈酸/油酸诱导的肝脂肪变性和炎症。
- 肝细胞DUSP12缺失小鼠出现饮食诱导的高胰岛素血症、肝脂肪变性和胰岛素敏感性下降。
- DUSP12过表达可减轻高脂饮食诱导的肝脂肪变性、胰岛素抵抗和炎症。
核心结论
- DUSP12是肝脂肪变性的正向调节因子,为NAFLD提供了潜在的治疗机会。
研究设计与样本
- 研究在L02细胞中采用棕榈酸/油酸处理,并使用肝细胞特异性DUSP12缺失小鼠和高脂饮食或高脂高胆固醇饮食喂养模型,以及DUSP12过表达肝细胞。
主要发现
- DUSP12在L02细胞中保护免受棕榈酸/油酸处理后的肝脂肪变性和炎症。
- 肝细胞特异性DUSP12缺失小鼠在高脂饮食和高脂高胆固醇饮食下出现高胰岛素血症、肝脂肪变性和胰岛素敏感性下降。
- DUSP12过表达肝细胞可减轻高脂饮食诱导的肝脂肪变性、胰岛素抵抗和炎症。
- DUSP12缺失时脂肪变性以ASK1升高为特征,ASK1介导MAPK通路和肝脏代谢。
- DUSP12与ASK1物理结合,促进其去磷酸化,并抑制其对ASK1相关蛋白、JUN N末端激酶和p38 MAPK的作用,从而在高脂条件下抑制脂肪生成。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nonalcoholic fatty liver disease (NAFLD) has become the most common cause of chronic liver disease worldwide. Due to the growing economic burden of NAFLD on public health, it has become an emergent target for clinical intervention. DUSP12 is a member of the dual specificity phosphatase (DUSP) family, which plays important roles in brown adipocyte differentiation, microbial infection, and cardiac hypertrophy. However, the role of DUSP12 in NAFLD has yet to be clarified. Here, we reveal that DUSP12 protects against hepatic steatosis and inflammation in L02 cells after palmitic acid/oleic acid treatment. We demonstrate that hepatocyte specific DUSP12-deficient mice exhibit high-fat diet (HFD)-induced and high-fat high-cholesterol diet-induced hyperinsulinemia and liver steatosis and decreased insulin sensitivity. Consistently, DUSP12 overexpression in hepatocyte could reduce HFD-induced hepatic steatosis, insulin resistance, and inflammation. At the molecular level, steatosis in the absence of DUSP12 was characterized by elevated apoptosis signal-regulating kinase 1 (ASK1), which mediates the mitogen-activated protein kinase (MAPK) pathway and hepatic metabolism. DUSP12 physically binds to ASK1, promotes its dephosphorylation, and inhibits its action on ASK1-related proteins, JUN N-terminal kinase, and p38 MAPK in order to inhibit lipogenesis under high-fat conditions. Conclusion: DUSP12 acts as a positive regulator in hepatic steatosis and offers potential therapeutic opportunities for NAFLD.
引用
- Huang Z, Wu LM, Zhang JL, et al. Dual Specificity Phosphatase 12 Regulates Hepatic Lipid Metabolism Through Inhibition of the Lipogenesis and Apoptosis Signal-Regulating Kinase 1 Pathways. Hepatology. 2019. PMID: 30820969. doi:10.1002/hep.30597
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。